<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157181</url>
  </required_header>
  <id_info>
    <org_study_id>NHL 4-2004</org_study_id>
    <nct_id>NCT02157181</nct_id>
  </id_info>
  <brief_title>Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab</brief_title>
  <official_title>Study on the Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jurgen Barth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the effectiveness (rate of complete remissions, total remission rate and
      duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous
      cladribine (LITAK®) plus anti-CD20* antibody rituximab in patients requiring treatment for
      relapsed hairy cell leukaemia or hairy cell leukaemia variant independent of any previous
      therapy.

      CD20* = cluster of differentiation antigen 20
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a prospective, multi-centre, open Phase II study on patients with hairy cell
      leukaemia variant or with relapsed hairy cell leukaemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete remissions (CR)</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>Determination of the rate of complete remission and duration of remission after one cycle of subcutaneous cladribine (LITAK®) plus four administrations of rituximab
in patients with hairy cell leukaemia variant
in patients with relapsed hairy cell leukaemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall remission rate (ORR)</measure>
    <time_frame>4 months after treatment</time_frame>
    <description>The rate of CR + PR will be determined</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute and late toxicity</measure>
    <time_frame>From day 1 of treatment period up to 120 months</time_frame>
    <description>All kind of adverse events, laboratory abnormalities, infections, unplanned hospitalisations will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Degree of induced immunodeficiency</measure>
    <time_frame>From day 1 of treatment period up to 120 months</time_frame>
    <description>Degree of immunosupression with CD4/CD8 quotient as indicating biomarker will be measured.
Duration of immunosupression as well as infectious and other complications which result from therapy will be reported</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of secondary neoplasia during the life-long follow-up period</measure>
    <time_frame>From day 1 of treatment period up to 120 months</time_frame>
    <description>Rate of secondary neoplasia as safety issue will be determined</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From achieving a remission until death</time_frame>
    <description>Determination of the overall survival times of all patients</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Hairy Cell Leukemia (HCL)</condition>
  <arm_group>
    <arm_group_label>HCL, 2CdA +/- Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk stratification
HCL variant will be treated with cladribine plus rituximab, independent of previous therapy
Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is &lt; 3 years.
All repeated relapses (&gt; 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.
Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion
Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is &gt; 3 years.
Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2CdA +/- Rituximab</intervention_name>
    <description>Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion</description>
    <arm_group_label>HCL, 2CdA +/- Rituximab</arm_group_label>
    <other_name>Cladribine, Syn 2CdA, (LITAK®) 0.14 mg/kg</other_name>
    <other_name>Rituximab (Mabthera®; Rituxan®) 375 mg/m²</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically verified hairy cell leukaemia (HCL) Hairy cell leukaemia
             variant (HCLv) or

          -  Relapse of hairy cell leukaemia after therapy with cladribine or pentostatin

          -  Need for treatment is indicated (see 4.3 below)

          -  Age at least 18 years

          -  General state of health according to WHO 0-2

          -  Written declaration of consent by the patient

          -  Current histology, which should not be older than 6 months, is necessary

        Exclusion Criteria:

          -  Patients, who do not fulfil the above-mentioned inclusion criteria.

          -  Patients with severe functional limitations of the heart according to New York Heart
             Association III / IV, of the lung according to WHO degree III / IV, the liver
             (bilirubin &gt; 2mg/dl, alkaline phosphatase, raised GOT and GPT (glutamate- pyruvate
             transaminase) values more than twice normal), diseases of the central nervous system,
             including psychoses. Creatinine &gt; 2 mg/dl, or creatinine clearance &lt; 50 mg/min

          -  Patients with proven HIV infections

          -  Patients with active hepatitis

          -  Patients with other florid infections

          -  Patients with anamnesis / diagnosis of another malignant disease (other than
             nonmelanoma associated skin tumours or stage 0 in situ carcinoma of the cervix)

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias J Rummel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Justus-Liebig-University | University Hospital | Medicinal Clinic IV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Ansbach</city>
        <zip>91522</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Celle</city>
        <zip>29221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic | Med. Cinic IV Justus-Liebig-University</name>
      <address>
        <city>Gießen</city>
        <zip>3592</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelm-Anton-Hospital</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Hagen gem. GmbH</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meditinische Hochschule (MHH)</name>
      <address>
        <city>Hannover</city>
        <zip>30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne/ Klinikum der Ruhr-Universität Bochum</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Hilden</city>
        <zip>40721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Idar-Oberstein</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Schwäbisch Gmünd / Staufer Klinik</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>München</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Neunkirchen</city>
        <zip>66538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Niddatal</city>
        <zip>61194</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Nürnberg</city>
        <zip>90449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Klinikum Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Pforzheim</city>
        <zip>75179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann gGmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Krankenhaus</name>
      <address>
        <city>Potsdam</city>
        <zip>14471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Krankenhaus</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Villingen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community based hemato-oncology medical office</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stil-info.de/index.php?id=260</url>
    <description>Homepage of StiL = Study group indolent Lymphomas</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Jurgen Barth</investigator_full_name>
    <investigator_title>Professor Dr. med Mathias Rummel</investigator_title>
  </responsible_party>
  <keyword>HCL variant</keyword>
  <keyword>HCL relapse</keyword>
  <keyword>Risk stratified</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

